The Lancet Diabetes and Endocrinology, 9(10), 653662
Recent Mintel research covers the impact of GLP-1 drugs on the food and drink industry (client access only) and our findings point out that previous attempts to medicate away obesity have failed
Wegovy (Semaglutide Injection) Wegovy utilizes semaglutide, just like Ozempic, and is administered weekly for weight management aimed at individuals with a BMI of 30 or higher, or 27 with additional weight-linked conditions
Thats why it is available in three different concentrations
Moreover, no specific standardized and repeatable assessment tools have been implemented to verify the non-seizure benefits of KDTs on other disease aspects such as sleep, attention, motor performance, and behavior
doi: 10.1016/j.fct.2010.11.032